LIQUID BIOPSY SHOWCASE
PRESENTATION: Thursday, June 30, 2022
2:45 PM PT/5:45 PM ET
SESSION: Liquid Biopsy Showcase
JP Hinestrosa, Ph.D., Sr. Director, Research, Biological Dynamics will discuss the company’s disruptive technology designed to advance early cancer detection by leveraging its proprietary Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.
PRESENTATION ABSTRACT
Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.
The Liquid Biopsy Showcase features selected liquid biopsy companies that are advancing the development of tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
PMWC, the “Precision Medicine World Conference” is the largest annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration in an effort to accelerate the development and spread of precision medicine.
Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology in clinical implementation (e.g., cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors
